GEFITINIB

Background Information:

The first selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase domain.

Reference:

1. Oxnard GR, Miller VA. Use of erlotinib or gefitinib as initial
therapy in advanced NSCLC. Oncology (Williston Park). 2010 Apr
30;24(5):392-9. Review. Review. Japanese.
2. Neal JW, Sequist LV. First-line use of EGFR tyrosine kinase
inhibitors in patients with NSCLC containing EGFR mutations. Clin Adv
Hematol Oncol. 2010 Feb;8(2):119-26. Review.
3. Funato T, Takeda M. [Current update and testing procedures for
genetic diagnosis in malignant neoplasm: additional information on
pathological tests]. Rinsho Byori. 2010 Feb;58(2):169-74.

APIM050154: GEFITINIB

CAS No.: 184475-35-2.
Molecular Formula: C₂₂H₂₄ClFN₄O_3.
Molecular Weight: 446.9.
Purity: > 99% (HPLC).
QC: ¹HNMR, HPLC.
Solubility: Soluble in DMSO.
Storage: Store at 0°C (short term), -20°C (long term), desiccated.